According to Barcelona Clinic Liver Cancer, the recommended first-line treatment for patients with intermediate stage of hepatocellular carcinoma (HCC) is transarterial chemoembolization. Patients with intermediate stage of HCC represent 20% with a 2-year survival of approximately 50%. Nowadays, transarterial therapies have proved precious in the treatment of hepatic malignancies. During the last years, there were important developments in practiced transarterial therapies and their efficacy is still controversial. The purpose of this review is to discuss in further details these transarterial therapies that have been used to treat cases of HCC.
Chegai, F., Orlacchio, A., Merolla, S., Monti, S., Mannelli, L. (2015). Intermediate hepatocellular carcinoma: the role of transarterial therapy. HEPATIC ONCOLOGY, 2(4), 397-408 [10.2217/hep.15.32].
Intermediate hepatocellular carcinoma: the role of transarterial therapy
ORLACCHIO, ANTONIO;
2015-04-01
Abstract
According to Barcelona Clinic Liver Cancer, the recommended first-line treatment for patients with intermediate stage of hepatocellular carcinoma (HCC) is transarterial chemoembolization. Patients with intermediate stage of HCC represent 20% with a 2-year survival of approximately 50%. Nowadays, transarterial therapies have proved precious in the treatment of hepatic malignancies. During the last years, there were important developments in practiced transarterial therapies and their efficacy is still controversial. The purpose of this review is to discuss in further details these transarterial therapies that have been used to treat cases of HCC.| File | Dimensione | Formato | |
|---|---|---|---|
|
04 intermediate hepatocellular carcinoma- the role of transarterial therapy.pdf
accesso aperto
Licenza:
Copyright dell'editore
Dimensione
1.52 MB
Formato
Adobe PDF
|
1.52 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
